Market Overview

UPDATE: Hilliard Lyons Upgrades HopFed Bancorp to Long-Term Buy on Earnings, Capitalization Outlook

Related HFBC
How To Make 2.7 Times The Market During 13F Season
Exclusive: A Look Into HopFed Bancorp, Inc. With CEO John Peck

Hilliard Lyons raised its rating on HopFed Bancorp (NASDAQ: HFBC) from Neutral to Long-term Buy with an $11 price target.

Hilliard Lyons said, "Our more favorable view of the company is based largely on higher earnings due to financial engineering coupled with improving credit quality as opposed to growth. In order to sustain earnings momentum the bank will need to begin growing loans again, but at this junction we do not see that as necessary in order to push the stock price higher. Further, a strong capital position, could allow the board to raise the common dividend in the 2H13 if our favorable outlook prevails."

HopFed Bancorp closed at $8.06 on Thursday.

Latest Ratings for HFBC

Apr 2013Hilliard LyonsDowngradesLong-Term BuyNeutral
Nov 2012Hilliard LyonsUpgradesNeutralLong-Term Buy

View More Analyst Ratings for HFBC
View the Latest Analyst Ratings

Posted-In: Hilliard LyonsAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (HFBC)

View Comments and Join the Discussion!

Latest Ratings

SBEvercore ISI GroupUpgrades4.5
PTIRBC CapitalUpgrades0.0
GPSJP MorganDowngrades24.0
GIIIB. Riley FBRUpgrades47.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Miller Tabak Upgrades Home Properties to Strong Buy, Sets $70.31 PT

UPDATE: Oppenheimer Downgrades Corcept Therapeutics to Perform on Disappointing Sales